Braxia Scientific Reports Q3 2022 Financial Results; Company Leads in Psychedelic Research, Access and Therapist Training with First Multi-Dose Psilocybin Trial in Canada
Braxia Scientific (BRAX) reported quarterly financial results including $324K in revenue (up 13.3% year-over-year), $7.64M in cash, and a $2.52M net loss.
